DDInter1042 DDInter1524
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A derivative of procaine with less CNS action.
Procainamide {u} (Compound) resembles {v} (Compound) Aminohippurate
Procainamide {u} (Compound) resembles {v} (Compound) Procaine
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Procainamide {u} (Compound) binds {v} (Gene) SCN11A
Procainamide {u} (Compound) causes {v} (Side Effect) Vomiting
Procainamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alosetron
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Procainamide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Procainamide (Compound) resembles Aminohippurate (Compound)
Procainamide (Compound) resembles Procaine (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Procainamide (Compound) binds SCN11A (Gene)
Procainamide (Compound) causes Vomiting (Side Effect)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Alosetron
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Procainamide may lead to a major life threatening interaction when taken with Cladribine
Procainamide may lead to a major life threatening interaction when taken with Ivosidenib
Procainamide (Compound) resembles Lidocaine (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine